{
    "id": 536,
    "fullName": "NF1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "NF1 dec exp indicates decreased expression of the Nf1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4763,
        "geneSymbol": "NF1",
        "terms": [
            "NF1",
            "NFNS",
            "VRNF",
            "WSS"
        ]
    },
    "variant": "dec exp",
    "createDate": "05/13/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 189,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I clinical trials, increased expression of Nf1 conferred resistance to Tarceva (erlotinib) in lung adenocarcinoma patients (PMID: 24535670).",
            "molecularProfile": {
                "id": 595,
                "profileName": "NF1 dec exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 268,
                    "pubMedId": 24535670,
                    "title": "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24535670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 827,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knockdown of NF1 in a BRAF V600E melanoma cell line confered resistance to the RAF inhibitor GDC0879 through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 819,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the shRNA knockdown of NF1 in a BRAF V600E melanoma cell line conferred resistance to RAF inhibitor PLX4720 through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 828,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NF1 knockdown in a BRAF V600E melanoma cell line conferred partial resistance to the combined treatment of the RAF inhibitor PLX4720 and the MEK inhibitor selumetinib (AZD6244) (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 826,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the shRNA knockdown of NF1 in a BRAF V600E melanoma cell line confers resistance to RAF inhibitor Zelboraf (vemurafenib) through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 824,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knockdown of NF1 in a BRAF V600E melanoma cell line demonstrated partial resistance to the pan-RAF inhibitor AZ628 (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 822,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of NF1 in a BRAF V600E melanoma cell line conferred resistance to MEK inhibitor selumetinib (AZD6244) through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 825,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of NF1 in a melanoma cell line harboring a BRAF V600E mutation did not affect sensitivity to the ERK inhibitor VTX-11e (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1094,
                "therapyName": "VTX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 823,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of C-RAF in a BRAF V600E melanoma cell line with decreased NF1 expression restored sensitivity to the MEK inhibitor selumetinib (AZD6244) (PMID: 23288408).",
            "molecularProfile": {
                "id": 1178,
                "profileName": "BRAF V600E NF1 dec exp RAF1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combined shRNA knockdown of NF1 and RAF1 in a melanoma cell line with BRAF V600E mutation was sensitive to RAF inhibitor PLX4720 (PMID: 23288408).",
            "molecularProfile": {
                "id": 1178,
                "profileName": "BRAF V600E NF1 dec exp RAF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant melanoma cells with decreased Nf1 expression level via shRNA knock-down were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26407,
                "profileName": "BRAF mut NF1 dec exp"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of NF1 in transformed cells expressing a MET exon 14 skipping mutation induced resistance to Xalkori (crizotinib) in culture (PMID: 31548343).",
            "molecularProfile": {
                "id": 34026,
                "profileName": "MET del exon14 NF1 dec exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16918,
                    "pubMedId": 31548343,
                    "title": "Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31548343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Mekinist (trametinib) with Xalkori (crizotinib) restored sensitivity to Xalkori (crizotinib) in transformed cells expressing a MET exon 14 skipping mutation and knockdown of NF1 in culture (PMID: 31548343).",
            "molecularProfile": {
                "id": 34026,
                "profileName": "MET del exon14 NF1 dec exp"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16918,
                    "pubMedId": 31548343,
                    "title": "Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31548343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20273,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Faslodex (fulvestrant) synergistically inhibited growth of Esr1-positive breast cancer cells with knocked down Nf1 expression by siRNA in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20269,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of NF1 with siRNA or shRNA led to decrease Nf1 protein expression and resistance to Faslodex (fulvestrant) treatment in Esr1-positive breast cancer cell lines in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of NF1 with siRNA or shRNA led to decrease Nf1 protein expression and resistance to Nolvadex (tamoxifen) treatment in Esr1-positive breast cancer cell lines in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20272,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Nolvadex (tamoxifen) synergistically inhibited growth of Esr1-positive breast cancer cells with knocked down Nf1 expression by siRNA in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 3542,
                "therapyName": "Palbociclib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 595,
            "profileName": "NF1 dec exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4540,
                    "name": "mTOR Inhibitor",
                    "profileName": "NF1 dec exp"
                },
                {
                    "id": 4537,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NF1 dec exp"
                },
                {
                    "id": 4538,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NF1 dec exp"
                },
                {
                    "id": 4539,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NF1 dec exp"
                }
            ]
        },
        {
            "id": 1177,
            "profileName": "BRAF V600E NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1178,
            "profileName": "BRAF V600E NF1 dec exp RAF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26407,
            "profileName": "BRAF mut NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34026,
            "profileName": "MET del exon14 NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34993,
            "profileName": "ESR1 pos NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}